JP6722599B2 - 全身性炎症反応症候群の治療のための間葉系間質細胞 - Google Patents

全身性炎症反応症候群の治療のための間葉系間質細胞 Download PDF

Info

Publication number
JP6722599B2
JP6722599B2 JP2016575950A JP2016575950A JP6722599B2 JP 6722599 B2 JP6722599 B2 JP 6722599B2 JP 2016575950 A JP2016575950 A JP 2016575950A JP 2016575950 A JP2016575950 A JP 2016575950A JP 6722599 B2 JP6722599 B2 JP 6722599B2
Authority
JP
Japan
Prior art keywords
cells
composition
mscs
sepsis
asc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016575950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520583A (ja
JP2017520583A5 (cg-RX-API-DMAC7.html
Inventor
ダレマンズ，ウィルフリード
ロムバード，エレウテリオ
デッカー，ロバート
Original Assignee
ティジェニクス エス．エー．ユー．
ティジェニクス エス．エー．ユー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティジェニクス エス．エー．ユー．, ティジェニクス エス．エー．ユー． filed Critical ティジェニクス エス．エー．ユー．
Publication of JP2017520583A publication Critical patent/JP2017520583A/ja
Publication of JP2017520583A5 publication Critical patent/JP2017520583A5/ja
Application granted granted Critical
Publication of JP6722599B2 publication Critical patent/JP6722599B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
JP2016575950A 2014-06-30 2015-06-30 全身性炎症反応症候群の治療のための間葉系間質細胞 Active JP6722599B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14175095.0 2014-06-30
EP14175095 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (3)

Publication Number Publication Date
JP2017520583A JP2017520583A (ja) 2017-07-27
JP2017520583A5 JP2017520583A5 (cg-RX-API-DMAC7.html) 2018-08-09
JP6722599B2 true JP6722599B2 (ja) 2020-07-15

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575950A Active JP6722599B2 (ja) 2014-06-30 2015-06-30 全身性炎症反応症候群の治療のための間葉系間質細胞

Country Status (14)

Country Link
US (2) US20170151284A1 (cg-RX-API-DMAC7.html)
EP (1) EP3160481B1 (cg-RX-API-DMAC7.html)
JP (1) JP6722599B2 (cg-RX-API-DMAC7.html)
KR (1) KR102213527B1 (cg-RX-API-DMAC7.html)
CN (1) CN106573017B (cg-RX-API-DMAC7.html)
AU (1) AU2015283662B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016030758B8 (cg-RX-API-DMAC7.html)
CA (1) CA2953884C (cg-RX-API-DMAC7.html)
IL (1) IL249814B (cg-RX-API-DMAC7.html)
MX (1) MX381544B (cg-RX-API-DMAC7.html)
NZ (1) NZ727950A (cg-RX-API-DMAC7.html)
RU (1) RU2715866C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201610844PA (cg-RX-API-DMAC7.html)
WO (1) WO2016001846A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017094260A1 (ja) * 2015-12-01 2017-06-08 学校法人 慶應義塾 脊椎動物の脂肪組織由来間葉系細胞株の製造方法
US11701389B2 (en) * 2016-03-09 2023-07-18 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
US11963984B2 (en) 2017-02-28 2024-04-23 Université De Lorraine Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis
WO2019084010A1 (en) 2017-10-26 2019-05-02 Emory University MCL-1 INHIBITORS, COMPOSITIONS AND USES IN CANCER CARE
JP7343091B2 (ja) * 2018-06-05 2023-09-12 メディポスト・カンパニー・リミテッド 軟骨損傷関連の疾患を処置するための、ヒアルロン酸及び幹細胞を含む医薬組成物
CN113166729A (zh) * 2018-10-29 2021-07-23 渥太华医院研究院 过表达aoah的基因工程间充质干细胞及其用途
TW202146033A (zh) * 2020-01-30 2021-12-16 日商Ｊｃｒ製藥股份有限公司 包含源自牙髓的細胞之醫藥組成物
AU2022273715A1 (en) * 2021-05-13 2023-11-30 Primegen Us, Inc. Methods and compositions for treating liver disease
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502421A (ja) 1992-12-02 1997-03-11 シエル・インターナシヨナル・リサーチ・マートシヤツピイ・ベー・ブイ アゾキシシアノベンゼン誘導体
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
AU2005227295A1 (en) * 2004-03-22 2005-10-06 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
ES2589311T5 (es) 2005-09-23 2020-02-14 Tigenix S A U Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
KR102063069B1 (ko) * 2011-03-11 2020-01-08 칠드런'즈 메디컬 센터 코포레이션 중간엽 줄기 세포 엑소솜에 관련된 방법 및 조성물
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
IL249814B (en) 2020-02-27
BR112016030758B1 (pt) 2021-10-13
AU2015283662B2 (en) 2020-09-24
IL249814A0 (en) 2017-03-30
CN106573017B (zh) 2021-06-11
SG11201610844PA (en) 2017-01-27
CN106573017A (zh) 2017-04-19
US20170151284A1 (en) 2017-06-01
RU2715866C2 (ru) 2020-03-03
EP3160481A1 (en) 2017-05-03
JP2017520583A (ja) 2017-07-27
KR20170021343A (ko) 2017-02-27
WO2016001846A1 (en) 2016-01-07
MX2017000142A (es) 2017-07-28
AU2015283662A1 (en) 2017-01-19
BR112016030758B8 (pt) 2022-10-25
RU2016151738A3 (cg-RX-API-DMAC7.html) 2019-01-30
CA2953884A1 (en) 2016-01-07
US20200376038A1 (en) 2020-12-03
NZ727950A (en) 2022-07-01
MX381544B (es) 2025-03-12
CA2953884C (en) 2022-12-06
BR112016030758A2 (cg-RX-API-DMAC7.html) 2017-08-22
EP3160481B1 (en) 2020-09-09
KR102213527B1 (ko) 2021-02-09
RU2016151738A (ru) 2018-07-30

Similar Documents

Publication Publication Date Title
JP6722599B2 (ja) 全身性炎症反応症候群の治療のための間葉系間質細胞
JP6755850B2 (ja) 間葉系幹細胞の使用
JP6764912B2 (ja) 免疫調節活性を有する細胞集団、その調製方法および使用
JP6722598B2 (ja) 関節リウマチ治療のための間葉系間質細胞
Delgado et al. Uses of mesenchymal stem cells
HK1230927A1 (en) Uses of mesenchymal stem cells
AU2015268704A1 (en) Uses of mesenchymal stem cells

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200622

R150 Certificate of patent or registration of utility model

Ref document number: 6722599

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250